Pioneering perspectives in point-of-care manufacturing

Shaping the future of patient access to therapies

Point-of-care (PoC) cell manufacturing, a decentralized approach where cell therapies are produced locally at or near hospitals, presents a transformative opportunity to expand access to life-saving treatments.1 Unlike the traditional centralized model, where possible disadvantages such as logistical challenges, limited flexibility, and high costs might limit patient access to cell therapies, PoC cell manufacturing networks could streamline tailored therapy production to deliver therapies faster to patients.2

Listen to experiences from the field of how PoC cell manufacturing is overcoming barriers to bring care closer to patients, sign up to our clinical newsletter to stay up to date in the field, and make it realistic for you by exploring further information on PoC cell manufacturing for your indication of interest.

Speaker headshot with microphone icon on a vibrant branded background

Revolutionizing brain cancer treatment: the promise of personalized immunotherapy

Prof. Misty Jenkins, Walter and Eliza Hall Institute (WEHI), Melbourne, Australia

Watch the interview (4:37 min)

Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain

Scaling cell therapy access: the impact of multi site manufacturing

Prof. Carlos Fernández de Larrea, Hospital Clinic Barcelona, Spain

Watch the interview (5:45 min)

Speaker headshot with microphone icon on a vibrant branded background

Point-of-care manufacturing regulations: collaborative efforts for safe therapies

Prof. Chi Kong Li, MD, Pediatric hematology/oncology, Chinese University of Hong Kong

Watch the interview (5:38 min)

Speaker headshot with microphone icon on a vibrant branded background

Racing against time – advancing cell therapies for brain cancer

David Reardon, MD, Dana-Farber Cancer Institute, USA

Watch the interview (5:24 min)

Stopping cancer before it starts: advancing preventive immunotherapy with dendritic cells

Prof. Jolanda de Vries, Radboud University Medical Center Nijmegen, The Netherlands

Watch the interview (5:38 min)

One infusion, lasting remission: cell therapy and the future of autoimmune disease care

Prof. Fabian Müller, University Hospital Erlangen, Germany

Watch the interview (6:45 min)

Stay connected with global PoC manufacturing and analytics experts

Sign up to our newsletter to keep up with the latest field developments and networking events

Close up of clinical employee in clean room attire starting a cell manufacturing process on the CliniMACS Prodigy​

PoC manufacturing and analytics for your indication

You have previously chosen International as your location.
What do you want to do?